During the last session, Denali Therapeutics Inc (NASDAQ:DNLI)’s traded shares were 0.86 million, with the beta value of the company hitting 1.43. At the end of the trading day, the stock’s price was $22.22, reflecting an intraday loss of -4.55% or -$1.06. The 52-week high for the DNLI share is $33.33, that puts it down -50.0 from that peak though still a striking 34.47% gain since the share price plummeted to a 52-week low of $14.56. The company’s market capitalization is $3.20B, and the average intraday trading volume over the past 10 days was 1.12 million shares, and the average trade volume was 947.77K shares over the past three months.
Denali Therapeutics Inc (DNLI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.18. DNLI has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.84.
Denali Therapeutics Inc (NASDAQ:DNLI) trade information
Denali Therapeutics Inc (DNLI) registered a -4.55% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -4.55% in intraday trading to $22.22, hitting a weekly high. The stock’s 5-day price performance is 2.54%, and it has moved by 3.59% in 30 days. Based on these gigs, the overall price performance for the year is 29.94%. The short interest in Denali Therapeutics Inc (NASDAQ:DNLI) is 7.84 million shares and it means that shorts have 9.04 day(s) to cover.
The consensus price target of analysts on Wall Street is $32.5, which implies an increase of 31.63% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $22 and $46 respectively. As a result, DNLI is trading at a discount of -107.02% off the target high and 0.99% off the low.
Denali Therapeutics Inc (DNLI) estimates and forecasts
Statistics show that Denali Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Denali Therapeutics Inc (DNLI) shares have gone down -5.89% during the last six months, with a year-to-date growth rate less than the industry average at -157.55% against 16.50. In the rating firms’ projections, revenue will decrease -97.19% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 9.18M as predicted by 14 analyst(s).
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -21.99%. While earnings are projected to return -162.05% in 2025.
DNLI Dividends
Denali Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Denali Therapeutics Inc (NASDAQ:DNLI)’s Major holders
Denali Therapeutics Inc insiders own 9.66% of total outstanding shares while institutional holders control 91.46%, with the float percentage being 101.24%. BAILLIE GIFFORD & CO is the largest shareholder of the company, while 325.0 institutions own stock in it. As of 2024-06-30, the company held over 13.76 million shares (or 9.2123% of all shares), a total value of $319.59 million in shares.
The next largest institutional holding, with 13.17 million shares, is of BLACKROCK INC.’s that is approximately 8.8181% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $305.91 million.
Also, the Mutual Funds coming in first place with the largest holdings of Denali Therapeutics Inc (DNLI) shares are Vanguard Specialized-Health Care Fund and Smallcap World Fund . Data provided on Oct 31, 2024 indicates that Vanguard Specialized-Health Care Fund owns about 8.8 shares. This amounts to just over 6.11 percent of the company’s overall shares, with a $195.48 million market value. The same data shows that the other fund manager holds slightly less at 5.98, or about 4.15% of the stock, which is worth about $132.84 million.
